A bullish post arguing Novo Nordisk is undervalued after a 60% drawdown, citing FDA approval of an oral Ozempic/weight-loss pill and predicting the stock will exceed $200.
NVO — LONG The author argues Novo Nordisk is a buy because it is down 60% from its all-time high and has released the first effective weight-loss pill, an oral form of Ozempic, which received FDA approval last week. The implied mechanism is that broad adoption of an oral GLP-1 weight-loss drug will drive revenue and re-rate the stock, with the author predicting it will pass $200 soon. No specific risk is stated beyond the framing of the prior drawdown.
its down 60% from all time high, its released the FIRST weight loss pill that actually works, ever, ozempic in pill form.
This Reddit post, published January 20, 2026, features u/Secure_Check_8485 discussing NVO. 1 trade idea extracted by AI with direction and confidence scoring.
Speakers: u/Secure_Check_8485 · Tickers: NVO